KLRG1 and glioblastoma: Tregs (Tc-II 11) were lower in RRMS and KLRG1+ (activated) CD8+ TTM (Tc-I-26 & Tc-I 33) and (activated) CD8+ TTE (Tc-I 19 & Tc-I 27) higher in RRMS in relation to glioblastoma patients similar to the comparison between RRMS patients and controls (Fig. 5R–U, W).